Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Fenofibrate also effective for women with type 2 diabetes

  • Comment

Blood-fat lowering drug fenofibrate is beneficial for women with type 2 diabetes, according to new research.

Investigators in Australia, New Zealand and Finland found that the lipid drug, which has been available since the mid-1970s, is just as effective in treating people of both genders with the long term condition.

“Both sexes with type 2 diabetes should be considered for fenofibrate therapy for cardioprotection”

Study authors

Previous studies, notably a recent trial in the US, have suggested that fenofibrate is not beneficial to some women.

The new research, however, reveals that the drug actually reduces levels of adverse blood fats, low-density lipoproteins (LDL), non-high-density lipoproteins (HDL) and apolipoprotein B more in women than in men.

This was the case independent of menopausal status and whether or not the women had also started taking statins.

Fenofibrate also reduces the risk of a cardiovascular outcome (cardiovascular death, fatal and non-fatal stroke and carotid and coronary revascularisation) by a greater amount in women than men − 30% compared to 13%.

The researchers, who were part of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, which was published in 2005, analysed a total of 9795 patients − 3657 women and 6138 men − with type 2 diabetes.

Participants were assigned a daily fenofibrate (200mg/day) or placebo tablet for a period of five years.

The findings also show that fenofibrate reduces the risk of cardiovascular outcome by 30% in women and 24% in men with very high triglyceride and low HDL levels, who are at high risk of diabetes complications.

The study authors said: “These data provide reassurance about fenofibrate efficacy in both women and men with type 2 diabetes.

“Both sexes with type 2 diabetes should be considered for fenofibrate therapy for cardioprotection… especially those with abnormal blood fats (dyslipidaemia),” they said.


  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs